Jove
Visualize
Contact Us

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

874
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
874
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

1.3K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.3K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

904
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
904
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

1.7K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.7K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

568
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
568
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

938
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
938

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prior Authorization for Sacral Nerve Stimulation in the Era of WISeR: Evaluation of U.S. Payer Coverage Policies.

Neurourology and urodynamics·2026
Same author

Barriers to Accessing Urogynecologic Care: A Single-Site Survey Study.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Interstitial Cystitis and Dietary Interventions: A Systematic Review.

International urogynecology journal·2026
Same author

Inflammatory Bowel Disease and Complications After Pelvic Organ Prolapse Repair.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Evaluating Outcomes of Sacral Neuromodulation in Patients With Multiple Sclerosis.

Neurourology and urodynamics·2026
Same author

Incidence of uterine cancer after supracervical hysterectomy.

Minerva obstetrics and gynecology·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Sep 21, 2025

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.4K

Does gabapentin impact response to anticholinergics for overactive bladder?

Kasey Roberts1, Angela Dao2, Anood Alfahmy3

  • 1Division of Female Pelvic Medicine and Reconstructive Surgery, Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. Kasey.roberts@UHhospitals.org.

International Urogynecology Journal
|June 1, 2022
PubMed
Summary
This summary is machine-generated.

Pre-existing gabapentin use did not improve treatment response in patients with overactive bladder receiving anticholinergics (AC). This study found no significant difference in therapeutic effects when gabapentin was used alongside AC.

Keywords:
AnticholinergicsGabapentinOveractive bladderResponse

More Related Videos

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

17.9K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.9K

Related Experiment Videos

Last Updated: Sep 21, 2025

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.4K
Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

17.9K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.9K

Area of Science:

  • Pharmacology
  • Urology
  • Clinical Medicine

Background:

  • Overactive bladder (OAB) is a common condition affecting quality of life.
  • Anticholinergics (AC) are a primary treatment for OAB.
  • The role of gabapentin in modulating AC efficacy for OAB is not well understood.

Purpose of the Study:

  • To investigate whether pre-existing gabapentin use influences the therapeutic response to anticholinergics in patients with overactive bladder.
  • To test the hypothesis that gabapentin improves response rates when used concurrently with AC.

Main Methods:

  • Retrospective chart review of female patients treated with AC between 2010-2018.
  • Stratification into AC-only and combination therapy (AC + gabapentin) groups.
  • Analysis of demographic, clinical characteristics, and treatment response, including subgroup analysis for chronic pain disorders.

Main Results:

  • Combination therapy did not lead to improved response rates compared to AC alone (41.6% vs. 47.7%, p=0.211), even after adjusting for confounders.
  • In patients with chronic pain, combination therapy showed a trend towards higher response (35.2% vs. 21.9%, p=0.0015), but this was not statistically significant after confounder adjustment.
  • Patients on combination therapy were more likely to have chronic pain, neuropathic pain, or use narcotics.

Conclusions:

  • Pre-existing gabapentin use does not appear to modulate the therapeutic effect of anticholinergics in patients with overactive bladder.
  • Gabapentin's potential role in OAB treatment alongside AC requires further investigation, particularly in specific patient subgroups.